Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SG-2501 by Hangzhou Sumgen Biotech for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...
SG-2501 by Hangzhou Sumgen Biotech for Primary Systemic Amyloidosis: Likelihood of Approval
SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Primary Systemic Amyloidosis. According to...
SG-2501 by Hangzhou Sumgen Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...
SG-2501 by Hangzhou Sumgen Biotech for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)....
SG-2501 by Hangzhou Sumgen Biotech for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...
SG-2501 by Hangzhou Sumgen Biotech for Refractory Multiple Myeloma: Likelihood of Approval
SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Refractory Multiple Myeloma. According to...
SG-2501 by Hangzhou Sumgen Biotech for Relapsed Multiple Myeloma: Likelihood of Approval
SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Relapsed Multiple Myeloma. According to...